Initiative for Medicines, Access & Knowledge
@imakglobal.bsky.social
We are a team of lawyers, scientists, and health experts challenging systemic injustice and advocating for health equity in drug development and access.
Pinned
🚨NEW: Today we published a new Overpatented, Overpriced report and launched an expanded and updated version of The Drug Patent Book, our searchable database of every patent we've uncovered on many of the most widely-used drugs in the U.S.
Reposted by Initiative for Medicines, Access & Knowledge
Jon Stewart and Lina Khan discuss how pharma companies build patent thickets.
November 19, 2025 at 3:10 PM
Jon Stewart and Lina Khan discuss how pharma companies build patent thickets.
NEWS: @tahiramin.bsky.social sat down with Nick Robertson of MLex to discuss how we’re helping Congress and the public understand the connection between patent abuse and high drug prices.
Read the interview: www.mlex.com/mlex/article...
Read the interview: www.mlex.com/mlex/article...
November 15, 2025 at 5:22 PM
NEWS: @tahiramin.bsky.social sat down with Nick Robertson of MLex to discuss how we’re helping Congress and the public understand the connection between patent abuse and high drug prices.
Read the interview: www.mlex.com/mlex/article...
Read the interview: www.mlex.com/mlex/article...
In our November newsletter, @tahiramin.bsky.social discusses findings from a new nationwide survey we commissioned from the Center for Opinion Research at Franklin and Marshall College.
www.i-mak.org/2025/11/10/n...
www.i-mak.org/2025/11/10/n...
New survey shows Americans want patent reform
Building a more just and equitable medicines system for all
www.i-mak.org
November 10, 2025 at 8:41 PM
In our November newsletter, @tahiramin.bsky.social discusses findings from a new nationwide survey we commissioned from the Center for Opinion Research at Franklin and Marshall College.
www.i-mak.org/2025/11/10/n...
www.i-mak.org/2025/11/10/n...
Sen. @hassan.senate.gov (D-NH): What are the real impacts of these patent games on patients?
Dr. @wbfeldman.bsky.social: These patent games can delay generic and biosimilar competition, which keep prices high...patients can’t afford their medications and we see worse clinical outcomes.
Dr. @wbfeldman.bsky.social: These patent games can delay generic and biosimilar competition, which keep prices high...patients can’t afford their medications and we see worse clinical outcomes.
October 27, 2025 at 11:09 PM
Sen. @hassan.senate.gov (D-NH): What are the real impacts of these patent games on patients?
Dr. @wbfeldman.bsky.social: These patent games can delay generic and biosimilar competition, which keep prices high...patients can’t afford their medications and we see worse clinical outcomes.
Dr. @wbfeldman.bsky.social: These patent games can delay generic and biosimilar competition, which keep prices high...patients can’t afford their medications and we see worse clinical outcomes.
Senator Susan Collins (R-ME) took time during a recent hearing on 340B reform to highlight the importance of patent reform.
October 27, 2025 at 11:05 PM
Senator Susan Collins (R-ME) took time during a recent hearing on 340B reform to highlight the importance of patent reform.
Last week, the Senate HELP Committee held a hearing on 340B reform. During the hearing, Sen. Hawley (R-MO) asked @wbfeldman.bsky.social how we can lower drug prices for Americans. Dr. Feldman outlined several steps we can take while making clear that patent reform is critical.
October 27, 2025 at 11:04 PM
Last week, the Senate HELP Committee held a hearing on 340B reform. During the hearing, Sen. Hawley (R-MO) asked @wbfeldman.bsky.social how we can lower drug prices for Americans. Dr. Feldman outlined several steps we can take while making clear that patent reform is critical.
Reposted by Initiative for Medicines, Access & Knowledge
TrumpRx and a most-favored nation policy won’t lower drug prices for patients. We need a government that is willing to stand up to corporate interests and actually become a most favored nation for patients, not pharmaceutical profits.
New op-ed for @statnews.com ↓
www.statnews.com/2025/10/24/t...
New op-ed for @statnews.com ↓
www.statnews.com/2025/10/24/t...
TrumpRx and a most favored nation policy won’t lower prices for patients
TrumpRx and a most-favored nation policy won’t lower prices for patients, writes the CEO and co-founder of I-MAK.
www.statnews.com
October 27, 2025 at 9:57 PM
TrumpRx and a most-favored nation policy won’t lower drug prices for patients. We need a government that is willing to stand up to corporate interests and actually become a most favored nation for patients, not pharmaceutical profits.
New op-ed for @statnews.com ↓
www.statnews.com/2025/10/24/t...
New op-ed for @statnews.com ↓
www.statnews.com/2025/10/24/t...
Reposted by Initiative for Medicines, Access & Knowledge
Thank to our colleagues of @imakglobal.bsky.social
for this strong analyse : www.statnews.com/2025/10/24/t...
for this strong analyse : www.statnews.com/2025/10/24/t...
TrumpRx and a most favored nation policy won’t lower prices for patients
TrumpRx and a most-favored nation policy won’t lower prices for patients, writes the CEO and co-founder of I-MAK.
www.statnews.com
October 27, 2025 at 10:10 PM
Thank to our colleagues of @imakglobal.bsky.social
for this strong analyse : www.statnews.com/2025/10/24/t...
for this strong analyse : www.statnews.com/2025/10/24/t...
🚨NEW: @nytimes.com reports on Colorado’s effort to curb the price of Enbrel.
“The fact the government never stepped in to rectify this extended patent monopoly is a case to be studied.” - @tahiramin.bsky.social
www.nytimes.com/2025/10/23/h...
“The fact the government never stepped in to rectify this extended patent monopoly is a case to be studied.” - @tahiramin.bsky.social
www.nytimes.com/2025/10/23/h...
Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices
www.nytimes.com
October 24, 2025 at 1:17 PM
🚨NEW: @nytimes.com reports on Colorado’s effort to curb the price of Enbrel.
“The fact the government never stepped in to rectify this extended patent monopoly is a case to be studied.” - @tahiramin.bsky.social
www.nytimes.com/2025/10/23/h...
“The fact the government never stepped in to rectify this extended patent monopoly is a case to be studied.” - @tahiramin.bsky.social
www.nytimes.com/2025/10/23/h...
🗞️ @statnews.com highlights key findings from a new national survey we commissioned to understand Americans’ top concerns on drug pricing.
🔗 www.statnews.com/pharmalot/20...
🔗 www.statnews.com/pharmalot/20...
October 22, 2025 at 3:40 PM
🗞️ @statnews.com highlights key findings from a new national survey we commissioned to understand Americans’ top concerns on drug pricing.
🔗 www.statnews.com/pharmalot/20...
🔗 www.statnews.com/pharmalot/20...
⏰ Our webinar is starting in 1 hour!
Tune in to learn about results from a new national survey showing strong bipartisan support for patent reform.
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
Tune in to learn about results from a new national survey showing strong bipartisan support for patent reform.
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
October 22, 2025 at 1:05 PM
⏰ Our webinar is starting in 1 hour!
Tune in to learn about results from a new national survey showing strong bipartisan support for patent reform.
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
Tune in to learn about results from a new national survey showing strong bipartisan support for patent reform.
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
In our October newsletter, @tahiramin.bsky.social asks a simple but critical questions about Merck's Keytruda Qlex: does it really count as an invention?
www.i-mak.org/2025/10/17/k...
www.i-mak.org/2025/10/17/k...
Keytruda Qlex: Where’s the invention?
Building a more just and equitable medicines system for all
www.i-mak.org
October 21, 2025 at 3:50 PM
In our October newsletter, @tahiramin.bsky.social asks a simple but critical questions about Merck's Keytruda Qlex: does it really count as an invention?
www.i-mak.org/2025/10/17/k...
www.i-mak.org/2025/10/17/k...
4 in 5 Americans support changes to patent laws to address drug pricing
Join us tomorrow at 10AM ET for a webinar unpacking results from a new national survey showing strong bipartisan support for patent reform.
RSVP here: www.i-mak.org/survey/
Join us tomorrow at 10AM ET for a webinar unpacking results from a new national survey showing strong bipartisan support for patent reform.
RSVP here: www.i-mak.org/survey/
October 21, 2025 at 1:03 PM
4 in 5 Americans support changes to patent laws to address drug pricing
Join us tomorrow at 10AM ET for a webinar unpacking results from a new national survey showing strong bipartisan support for patent reform.
RSVP here: www.i-mak.org/survey/
Join us tomorrow at 10AM ET for a webinar unpacking results from a new national survey showing strong bipartisan support for patent reform.
RSVP here: www.i-mak.org/survey/
Did you RSVP to our webinar?
A new national survey reveals bipartisan support for patent system reforms
🗓️ Wednesday, October 22
🕙 10AM ET
🗣️ @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
🎟️ www.i-mak.org/survey/
A new national survey reveals bipartisan support for patent system reforms
🗓️ Wednesday, October 22
🕙 10AM ET
🗣️ @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
🎟️ www.i-mak.org/survey/
October 19, 2025 at 9:01 PM
Did you RSVP to our webinar?
A new national survey reveals bipartisan support for patent system reforms
🗓️ Wednesday, October 22
🕙 10AM ET
🗣️ @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
🎟️ www.i-mak.org/survey/
A new national survey reveals bipartisan support for patent system reforms
🗓️ Wednesday, October 22
🕙 10AM ET
🗣️ @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
🎟️ www.i-mak.org/survey/
Reposted by Initiative for Medicines, Access & Knowledge
Looking forward to this conversation about drug prices next week!
JOIN US! On Wednesday, October 22 at 10AM ET we will host a webinar to discuss results from a new national survey revealing bipartisan momentum for patent system reform.
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
RSVP! www.i-mak.org/survey/
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
RSVP! www.i-mak.org/survey/
October 17, 2025 at 7:00 PM
Looking forward to this conversation about drug prices next week!
JOIN US! On Wednesday, October 22 at 10AM ET we will host a webinar to discuss results from a new national survey revealing bipartisan momentum for patent system reform.
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
RSVP! www.i-mak.org/survey/
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
RSVP! www.i-mak.org/survey/
October 17, 2025 at 6:13 PM
JOIN US! On Wednesday, October 22 at 10AM ET we will host a webinar to discuss results from a new national survey revealing bipartisan momentum for patent system reform.
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
RSVP! www.i-mak.org/survey/
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
RSVP! www.i-mak.org/survey/
Swipe to see how readers are reacting 👇
October 14, 2025 at 7:45 PM
Swipe to see how readers are reacting 👇
🚨 @washingtonpost.com reports on Colorado’s effort to lower the price of Enbrel—the latest state-level move to curb patent abuse in order to make life-saving drugs affordable for the patients that need them. The article features data from our team at I-MAK.
www.washingtonpost.com/health/2025/...
www.washingtonpost.com/health/2025/...
States fed up with high drug prices are cracking down
A Colorado panel voted Friday to cap the price for a best-selling drug from Amgen. It is one of four states that have passed legislation allowing price caps for specific prescriptions.
www.washingtonpost.com
October 14, 2025 at 7:44 PM
🚨 @washingtonpost.com reports on Colorado’s effort to lower the price of Enbrel—the latest state-level move to curb patent abuse in order to make life-saving drugs affordable for the patients that need them. The article features data from our team at I-MAK.
www.washingtonpost.com/health/2025/...
www.washingtonpost.com/health/2025/...
Merck is launching a patent-protected injectable version of Keytruda before biosimilars of the IV version of Keytruda enter the market.
Swipe to see reactions to the recent @nytimes.com story on Merck's product hopping scheme.
Swipe to see reactions to the recent @nytimes.com story on Merck's product hopping scheme.
September 24, 2025 at 9:39 PM
Merck is launching a patent-protected injectable version of Keytruda before biosimilars of the IV version of Keytruda enter the market.
Swipe to see reactions to the recent @nytimes.com story on Merck's product hopping scheme.
Swipe to see reactions to the recent @nytimes.com story on Merck's product hopping scheme.
“Merck is just the latest in a long line of drug companies that have introduced new versions of their medicines that allow them to keep charging high prices [to patients] even as their original patents expire.”
www.seattletimes.com/nation-world...
www.seattletimes.com/nation-world...
A new shot for cancer is convenient, but poised to keep prices high
To keep Keytruda revenue flowing, Merck developed a new version of the cancer treatment drug, given as a shot under the skin, which the FDA approved Friday.
www.seattletimes.com
September 24, 2025 at 9:23 PM
“Merck is just the latest in a long line of drug companies that have introduced new versions of their medicines that allow them to keep charging high prices [to patients] even as their original patents expire.”
www.seattletimes.com/nation-world...
www.seattletimes.com/nation-world...
1️⃣ Read The New York Time’s new investigation into Merck’s product hop on Keytruda.
2️⃣ Watch the video be published back in May detailing exactly how Merck is doing it.
2️⃣ Watch the video be published back in May detailing exactly how Merck is doing it.
Merck is changing the way Keytruda is delivered, from an IV infusion to a subcutaneous injection, so it can thwart biosimilar competition and continue price gouging people with cancer.
It's a tactic known as “product hopping" and it's a form of patent abuse. Here’s how it works.
It's a tactic known as “product hopping" and it's a form of patent abuse. Here’s how it works.
September 19, 2025 at 10:49 PM
1️⃣ Read The New York Time’s new investigation into Merck’s product hop on Keytruda.
2️⃣ Watch the video be published back in May detailing exactly how Merck is doing it.
2️⃣ Watch the video be published back in May detailing exactly how Merck is doing it.
@nytimes.com investigates Merck’s product hop on the cancer drug Keytruda.
“Merck has sought nearly 300 patents related to Keytruda, according to I-MAK. (Merck disputed I-MAK’s count but declined to provide a different figure.)"
www.nytimes.com/2025/09/19/h...
“Merck has sought nearly 300 patents related to Keytruda, according to I-MAK. (Merck disputed I-MAK’s count but declined to provide a different figure.)"
www.nytimes.com/2025/09/19/h...
A New Shot for Cancer Is Convenient, but Poised to Keep Prices High
www.nytimes.com
September 19, 2025 at 10:37 PM
@nytimes.com investigates Merck’s product hop on the cancer drug Keytruda.
“Merck has sought nearly 300 patents related to Keytruda, according to I-MAK. (Merck disputed I-MAK’s count but declined to provide a different figure.)"
www.nytimes.com/2025/09/19/h...
“Merck has sought nearly 300 patents related to Keytruda, according to I-MAK. (Merck disputed I-MAK’s count but declined to provide a different figure.)"
www.nytimes.com/2025/09/19/h...
🚨BREAKING: The New York Times investigates Merck’s product hop on Keytruda.
My team at @imakglobal.bsky.social has been warning for years that Merck would game the patent system to product hop its blockbuster cancer drug Keytruda. Today, the New York Times published an investigation into the company’s tactics.
www.nytimes.com/2025/09/19/h...
www.nytimes.com/2025/09/19/h...
A New Shot for Cancer Is Convenient, but Poised to Keep Prices High
www.nytimes.com
September 19, 2025 at 10:31 PM
🚨BREAKING: The New York Times investigates Merck’s product hop on Keytruda.
Reposted by Initiative for Medicines, Access & Knowledge
We have extensive data detailing Merck’s patenting tactics on Keytruda. I will share more here soon.
September 19, 2025 at 10:26 PM
We have extensive data detailing Merck’s patenting tactics on Keytruda. I will share more here soon.
Reposted by Initiative for Medicines, Access & Knowledge
My team at @imakglobal.bsky.social has been warning for years that Merck would game the patent system to product hop its blockbuster cancer drug Keytruda. Today, the New York Times published an investigation into the company’s tactics.
www.nytimes.com/2025/09/19/h...
www.nytimes.com/2025/09/19/h...
A New Shot for Cancer Is Convenient, but Poised to Keep Prices High
www.nytimes.com
September 19, 2025 at 10:26 PM
My team at @imakglobal.bsky.social has been warning for years that Merck would game the patent system to product hop its blockbuster cancer drug Keytruda. Today, the New York Times published an investigation into the company’s tactics.
www.nytimes.com/2025/09/19/h...
www.nytimes.com/2025/09/19/h...